Related Experiment Videos
Intrathecal orgotein
International Journal of Clinical Pharmacology Research
|January 1, 1985
Summary
Intrathecal injections of superoxide dismutase (SOD) showed potential benefits for multiple sclerosis patients, with many seeking further treatment. Lower SOD levels were observed in patients
Area of Science:
- Neurology
- Biochemistry
Background:
- Multiple sclerosis (MS) is a chronic neurological disease.
- Superoxide dismutase (SOD) is an enzyme with antioxidant properties.
Purpose of the Study:
- To evaluate the efficacy of intrathecal orgotein (a form of SOD) in patients with multiple sclerosis.
- To assess the levels of orgotein in cerebrospinal fluid (CSF) of MS patients.
Main Methods:
- 133 intrathecal injections of orgotein were administered to patients between 1971-78.
- Patient outcomes and requests for further treatment were recorded.
- Orgotein levels in CSF samples from 16 MS patients were determined.
Main Results:
- A subjective impression of improvement was noted in MS patients receiving orgotein.
- 45% of 58 MS patients requested additional intrathecal injections.
- One patient experienced relief from allergic headaches post-myelography.
- Orgotein levels in the CSF of MS patients were found to be significantly lower than previously reported.
Conclusions:
- Intrathecal orgotein may offer symptomatic relief for some multiple sclerosis patients.
- Further research is needed to understand the role of SOD levels in MS pathogenesis and treatment.